Index. E Early exposure, 15, 33, 165, 166, , 177, 181, 183, 184 Enantiomers, 46 47
|
|
- Delilah Henderson
- 5 years ago
- Views:
Transcription
1 Abbreviations AAPS ABE ACAT ADAM AEs AMA AMP ANDAs ANOVA AOA APCI API APSD ASEAN AUC AUEC BA BCS BDDCS BE CAT CFR CHMP CI C max CoA COPD CSF CTP American Association of Pharmaceutical Scientists Average bioequivalence Advanced compartmental absorption and transit Advanced dissolution, absorption, and metabolism Adverse events American Medical Association Adenosine monophosphate Abbreviated new drug applications Analysis of variance Administration on aging Atmospheric pressure chemical ionization Active pharmaceutical ingredient Aerodynamic particle size distribution Association of South East Asian Nations Area under the curve Area under the effect time curve Bioavailability Biopharmaceutics classification system Biopharmaceutics drug disposition classification system Bioequivalence Compartmental absorption and transit Code of Federal Regulations Committee for Human Medicinal Products Confidence interval Peak plasma concentration Certificates of analysis Chronic obstructive pulmonary disease Cerebrospinal fluid Child-Turcotte-Pugh L.X. Yu and B.V. Li (eds.), FDA Bioequivalence Standards, AAPS Advances in the Pharmaceutical Sciences Series 13, DOI / , The United States Government
2 460 Abbreviations CV DDIs DEPC DESI DMD DMPC DMPG DOPC DPI DPK DPPG DR EAEC ED50 EDTA ELISA EMA ESI ETEC FDA FEV1 FFD&C Act FPM GABA GE GI GIT GMR GSD HE HHS HILIC HPA HPLC HPMC HSPC HV HVDs IBE ICS INDs INR IR IS ISR Coefficient of variation Drug drug interactions Dierucoylphosphatidylcholine Drug efficacy study implementation Dermal microdialysis Dimyristoyl phosphatidylcholine Dimyristoyl phosphatidylglycerol Dioleoylphosphatidylcholine Dry powder inhalers Dermatopharmacokinetics Dipalmitoylphosphatidylglycerol Delayed release Enteroaggregative E. coli Median effective dose Ethylenediaminetetraacetic acid Enzyme-linked immunosorbent assay European Medicines Agency Electrospray ionization Enterotoxigenic Escherichia coli Food and Drug Administration Forced expiratory volume within 1 s The Federal Food, Drug, and Cosmetic Act Fine particle mass Gamma-aminobutyric acid Glucose excursion Gastrointestinal Gastrointestinal tract Geometric mean ratio Geometric standard deviation Hepatic encephalopathy Health and Human Services Hydrophilic interaction liquid chromatography Hypothalamic pituitary adrenal axis High performance liquid chromatography Hydroxypropyl methylcellulose Hydrogenated soy phosphatidylcholine Highly variable Highly variable drugs Individual bioequivalence Orally inhaled corticosteroids Investigational new drug applications International normalized ratio Immediate release Internal standard Incurred sample reanalyses
3 Abbreviations 461 ITT IVIVC IVRT LABAs LBA LC LD50 LIMS LLE LLOQ LMWH mcsrs MD MDD MDP ME MEC MELD MHE MIP MITT MMAD MmCSRS MMF MPA MR MRM MRT MS MTC MVL NCEs NDAs NIR NME NO NSAID NTI OGD OIP OTA paucs PBC PBE PBPK Intent-to-treat In vitro in vivo correlation In vitro drug release testing Long-acting β2 adrenoceptor agonists Ligand binding assays Liquid chromatography Median lethal dose Laboratory information management systems Liquid liquid extraction Lower limit of quantitation Low molecular weight heparin Modified chi-square ratio statistic Multiple dose Maximum daily dose Muramyl dipeptide Matrix effects Minimum effective concentrations Model for end stage liver disease Minimal hepatic encephalopathy Molecularly imprinted polymer Modified intent-to-treat Mass median aerodynamic diameter The median of modified chi-square ratio Mycophenolate mofetil Mycophenolic acid Modified release Multiple reaction monitoring Mean residence time Mass spectrometry Minimum toxic concentrations Multivesicular liposomes New chemical entities New drug applications Near infrared New molecular entity Nitric oxide Non-steroidal anti-inflammatory drug Narrow therapeutic index Office of Generic Drugs Orally inhaled products Office of Technology Assessment Partial area under the curve Population bioequivalence criteria Population bioequivalence Body physiologically based pharmacokinetic
4 462 Abbreviations PC20 PD PD20 PDR PEG P-gp PK PP PP PSD PSE PT QbD QC R RES RLD RMSE RSABE SABAs SAC SD SD SEDDS SIF SIL SONIC SPE SRM T TD TE TEWL TK TLUS T max TNSS UCB UHPLC ULOQ US-FDA UV VCA WHO WSV Provocative concentration that produces a 20 % decrease in FEV1 Pharmacodynamic Provocative dose that produces a 20 % decrease in FEV1 Population difference ratio Polyethylene glycol P-glycoprotein Pharmacokinetic Per-protocol Protein precipitation Particle size distribution Portal systemic encephalopathy Prothrombin Quality-by-design Quality controls Reference Reticuloendothelial system Reference listed drug Root mean square error Reference-scaled average bioequivalence Short-acting β2 adrenoceptor agonists Single actuation content Single dose Standard deviation Self-emulsifying drug delivery system Simulated intestinal fluid Stable isotope labeled Spectrum of neurocognitive impairments in cirrhosis Solid phase extraction Selected reaction monitoring Test Travelers diarrhea Therapeutically equivalent Transepidermal water loss Toxicokinetic Time to last unformed stool Time to peak concentration Total nasal symptom scores Upper-confidence bound Ultra-high performance liquid chromatography Upper limit of quantitation US Food and Drug Administration Ultraviolet Vasoconstrictor assay World Health Organization Within-subject variability
5 Index A Abbreviated new drug applications (ANDAs), 30, 31, 103, , 113, 128, 148, 151, 197, 295, , 354, 355, 369, 370, 381, 383, 403 Aerodynamic particle size distribution (APSD), 39, , 374, 378, 407 Average bioequivalence (ABE), 7, 8, 12, 13, 15, 56, 59 60, 64, 65, 72, 73, 76 79, 88 89, 142, 143, 145, 147, 148, , 164, , , 312, 407 B Bioanalysis, 279, Bioanalytical method, 378, , 437, 441, 442, 444 Bioavailability (BA), 3, 29, 55, 93, 117, 163, 223, 242, 308, 336, 383, 394 Bioequivalence (BE), 1 22, 29 49, 55, 59 67, 77, 88, 89, , , , , , , , , , , , , , 417 Biomarkers, 205, 243, , 267, 268, 384, 423 Biopharmaceutics classification system (BCS), 2, 8 11, 38, 49, 95, , 107, 113, , 141, 318, 408, 409 Biopharmaceutics drug disposition classification system (BDDCS), 2, 11, 127 Biowaivers, 9 10, 38, 44, , 107, 109, , 201 C Carryover, 71, 80, 85, 90, 222 CAT model, 2, 10 11, Clinical endpoints, 17, 18, 22, 34, 37, 49, 75, 91 92, 218, 231, , 337, 350, 357, 386 Clinical endpoint study, 19, 20, 36 37, 55, 91, 216, 230, , , 296, 298, 301, 302, 307, 313, 318, 320, 326, 339, , 355, 357, 358, 362, 369, Clinical study, 149, 190, 215, , 246, 250, 269 Colesevelam, Comparative clinical effect, 241 Critical-dose drugs, 14, 193, 194, 199 Crossover design, 32, 40 43, 48, 66 74, 77 88, 90, 91, 101, 108, 138, 140, 141, 150, 155, 157, 206, 211 D Drug Price Competition and Patent Term Restoration Act, 4 5, 30, 245, 335 Drug release, 12, 21, 39, 164, 167, 168, , 177, 178, 183, 185, 276, 277, 280, 282, 283, 285, , 298, 307, 312, 313, 319, 321, 322, 351, 405 Dry powder inhalers (DPI), 19, , 376, , 384, 385, 388, 389 E Early exposure, 15, 33, 165, 166, , 177, 181, 183, 184 Enantiomers, L.X. Yu and B.V. Li (eds.), FDA Bioequivalence Standards, AAPS Advances in the Pharmaceutical Sciences Series 13, DOI / , The United States Government
6 464 Index Endogenous compounds, 47 49, 419, 423, 430 Excipient effects, , F Food-drug interaction, 100, 106 Food effects, 10, 95, 96, , 403 G Gastric emptying, 10, 12, 43, 93, 95 97, , 110, 118, 120, 122, 128, 129, 322, 396, 399, 400, 402, 403 Gastrointestinal drugs, 16 17, 20, 333 Gastrointestinal ph, Generic drug products, 6, 8, 13, 31, 112, 138, 140, 141, 149, 190, 204, 208, 215, 218, 237, 242, 243, 246, 247, 295, 298, 299, 338, 355, 360 Guidance, 2, 33, 59, 95, 121, 146, 172, 193, 217, 249, 275, 296, 338, 378, 402, 418 H Highly variable drugs, 2, 11 13, 32, 41, 49, 88, , 172, 204, 307, 379, 407 High metabolism, 11, 127 High permeability, 10, 103, 119, 122, 125, 126, 130, 132 High solubility, 10, 17, 103, 122, 129, 130, 298, 303, 318 I Incurred sample reanalysis (ISR), Individual bioequivalence (IBE), 2, 7 8, 13, 56, 63 66, 74, 84 88, 142, 206, 286 Inhalation products, 18 20, 36, 39 Intestinal transit, 10, 12, 41, 93, 97, , 122, 131, 308, 399, 400 Investigational new drug, 30, 128, 378 In vitro and in vivo correlations (IVIVCs), 289, 393, In vitro binding assay, 300 In vitro dissolution, 10, 17, 38 39, 43, 44, 103, 105, 121, 128, 132, 183, 215, , 302, 303, , , 318, 321, 400, In vitro release testing, 351 L Lanthanum carbonate, 17, 39, 225, , 303, Liposome, 20 22, Local action, 18 20, 217, 242, 243, 315, 317, 370, 387 M Mesalamine, 16, 17, , 178, 296, , 326 Metabolites, 45 46, 48, 127, 181, 215, 216, 219, 253, 267, 297, 301, 302, 308, 309, 312, 408, 417, 418, 423, 425, 430, 434, , 445, Metered dose inhalers, 218, 227, 231, 232, , , 376, , 388, 389 Method validation, 223, 236, 417, 424, , 434, 435, 438 Methylphenidate extended-release products, Microdialysis, 230, 355, 358, 359 Modeling and simulation (M&S), 16, 22, 183, 221, Morphology, 277, 287 Multilamellar, , 282, 283, 289 Multiple dose (MD), 13, 19, 42, 43, 55, 56, 66, 164, 179, 228, 230, 316, 317, 334, 408 Multivesicular, 275, 277 N Narrow therapeutic index (NTI) drugs, 2, 5, 13 15, 32, 41, 49, 88, 128, , 407 Narrow therapeutic range, 14, 64, , 201, 205 Narrow therapeutic ratio, 4, 14, 193, 195 Narrow therapeutic window, 14, 105, 193 Nasal spray, 18, 19, 37, 217, 253, , , 379, 380, New drug application (NDA), 30, 110, 128, 148, 149, 180, 197, 295, 335, 337, 369, 370, 381, 383, 403 O Orlistat, 224, 225, 228, 230, 296, 302, 303, , 326, 383
7 Index 465 P Parallel design, 40, 41, 43, 66, 67, 79, 84, 90, 91, 262, 268, 301 Parent drug, 45 46, 253, 308, 309, 408, 430, 441, 447 Partial AUC (PAUC), 2, 15, 16, 33, 34, 149, , 303, 307, 312, 313, 326, 407, 408 Partial exposure, 15, Peak exposure, 15, 33 Pharmacodynamic endpoint, 35, 36, , 321, 378, 380 Pharmacodynamics, 14, 19, 20, 197, 215, 296, 300, 381, 383 Pharmacodynamic study, 36, 182, 183, 228, 382 Pharmacokinetics (PK), 5, 19, 29, 56, 163, 189, 215, 242, 273, 296, 334, 368, 398, 417 Physicochemical characterization, 274, , 313 Physiologically based absorption models, 406 Population bioequivalence (PBE), 56, 60 62, 73, 79 84, 287 R Racemate, Reference-scaled average bioequivalence approach, 13 15, 88 89, 108, 142, , , 209, 211, 312, 379 Regulation, 2 4, 29, 32, 49, 55, 66, 101, 102, 107, 129, 137, 163, 193, 195, 245, 246, 252, , 325, 336, 338, 347, 362, 417 Regulatory documentation, 438 Replicate study design, 8, 40, 147 Rifaximin, 17, 249, , 262, , 268, 269, 302, 303 S Sample analysis, 426, 430, 432, 433, , 440, 441, 445, Sample size, 12 14, 67, 72 75, , 145, 151, 172, 176, 177, 184, 201, 204, 221, 237, 379, 437, Single-dose (SD), 6, 19, 40 45, 48, 55, 90, 103, 108, 110, 138, 150, 164, 181, 182, , 227, 228, 232, 285, 310, 316, 378, 379, 383, 388, 408 Size, 2, 37, 67, 96, 139, 167, 198, 221, 247, 275, 313, 360, 370, 395, 421 Skin, 36, 118, 206, 220, 242, 280, 333 Skin stripping, 230, Solution, 6, 8, 10, 18, 30, 37, 43, , 129, 131, 163, 180, 243, 256, , 289, 298, 318, 322, 324, 336, 337, , 351, 361, 377, 379, 405, 423, 424, 430, 432, 442, 443, 446 Sprinkle study, Stability, 22, 31, 103, 123, 124, 127, 138, 234, 235, , 343, 347, 384, 421, 424, 425, , 435, , , 449, 450, 452 Study design, 5, 8, 12 15, 29, 36, 37, 40, 56, 66 74, 81, 86, 92, 108, , , 151, 152, 198, , , 227, 228, 232, 235, 237, 243, 248, 258, 357, 359, 371, , , 387, 408, 409 Study power, 72 74, 139, 140, 145, 149 Surface properties, 280, 374 Surrogate endpoint, 219, 243, T Tacrolimus, 45, 193, 194, 197, , 352 Topical products, 230, 304, 336, 337, 354, 356, 357 Total exposure, 15, 33, 164 U Unilamellar, , , 289 V Vancomycin, 16, 17, 259, 296, 302, 303, , 326 W Warfarin, 193, 194, 197, , 208 Z Zolpidem extended-release products, 15, 179,
Current Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationDraft Guidance on Fluticasone Propionate; Salmeterol Xinafoate. Fluticasone Propionate; Salmeterol Xinafoate. Powder/Inhalation
Reprinted from FDA s website by EAS Consulting Group, LLC Contains Nonbinding Recommendations Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate This draft guidance, once finalized, will represent
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationUSING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN
USING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN Christophe Tistaert PDMS Pharmaceutical Sciences Preformulation & Biopharmaceutics AAPS 2015, FLORIDA (USA) Canagliflozin An orally active
More informationGeneric Inhaled Medications
Generic Inhaled Medications Financial Interest Disclosure (over the past 24 months) Irvin Mayers Company Speaker Advisory Research Medimmune Novartis GSK Boehringer Ingelheim CADTH Health Canada Financial
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationScientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles
Scientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles Liang Zhao, Ph.D. Director, Division of Quantitative
More informationSOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS
SOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS Scott Haughie, M.Sc., Senior Director, Biostatistics IPAC-RS/UF Orlando Inhalation
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationDemonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products Extended Breakout Session 2: Biomarker Strategies Richard C. Ahrens, M.D. Partha Roy, Ph.D. Dale P. Conner, Pharm.D. Regulatory
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More informationEffect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs James E. Polli jpolli@rx.umaryland.edu April 26, 2016 Topics BCS Class 3 excipient study
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationCONTENT. i iv ix. SVKM s NMIMS, School of Pharmacy and Technology Management
CONTENT Chapter No. Title Page No. Abbreviations List of Figures List of Tables 1 Introduction 1 1.1 Practical aspects 4 1.2 Stability-indicating assay method (SIAM) 5 1.3 Regulatory aspects 6 1.4 Techniques
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationBioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry
Journal of Applied Bioanalysis http://dx.doi.org/10.17145/jab.18.010 COMMENTARY Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry Roland J.W.
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationOverview of Matrix Effects in Bioanalysis
Overview of Matrix Effects in Bioanalysis Patrick Bennett & Jing Tu PPD Laboratories 31March2017 Outline 1. Definitions 2. Overview of Matrix Effects 3. Regulatory guidance on matrix effect(s): FDA and
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationVolume 1(3) May-June 2013 Page 351
ISSN: 2321-5674(Print) BIOAVAILABILITY: CRITERIA FOR APPROVING A DRUG PRODUCT FOR MARKETING Sandhya Singh 1, Faheem Ajmal Ansari 1, Shravan Paswan 2*, Rnjan Kumar Sharma 2, Alok Ranjan Gaur 3 1 Azad Institute
More informationBCS: Dissolution Testing as a Surrogate for BE Studies
BCS: Dissolution Testing as a Surrogate for BE Studies Dirk M Barends National Institute of Public Health and the Environment The Netherlands APV / IKEV Seminar on Bioavailability and Bioequivalence, Istanbul,
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationConsiderations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products
Considerations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products Sven Stegemann Sept 16, 2015 Institute for Process and Particle Engineering, Pharmaceutical Engineering
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationCOMMITTEE ON MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 18 October 2007 Doc. Ref. CPMP/EWP/4151/00 Rev. 1 COMMITTEE ON MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE
More informationExcipient Interactions Relevant For BCS Biowaivers Peter Langguth
Excipient Interactions Relevant For BCS Biowaivers Peter Langguth Department of Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg University Mainz, Germany 3rd Symposium on Harmonization
More informationQualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations. Julie D. Suman, Ph.D. November 14, 2014
Qualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations Julie D. Suman, Ph.D. November 14, 2014 Objectives Container-Closure System Attributes Extractables Regulatory Expectations
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More informationPublic Assessment Report Scientific discussion. Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC
Public Assessment Report Scientific discussion Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC This module reflects the scientific discussion for the approval
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationREGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore
1 REGULATORY PERSPECTIVE Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore Contents 2 1. Role of Dissolution Testing in Generic Drug Approval 2. Dissolution Testing Recommendation for Solid Oral
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationSummary Chapter 8 CHAPTER 8. Summary. Page 173
CHAPTER 8 Summary Page 173 Chapter 2: Liquid Chromatography/Tandem Mass Spectrometry Method for Quantitative Estimation of PEG 400 and its Applications A rapid sensitive and selective MRM based method
More informationBiowaiver and Dissolution Profile Comparison
Biowaiver and Dissolution Profile Comparison Triporn Wattananat Bureau of Drug and Narcotic Department of Medical Sciences June 14, 2011 Biowaiver Outline: 1. Introduction 2. Biopharmaceutics Classification
More informationFDA Bioequivalence Standards
AAPS Advances in the Pharmaceutical Sciences Series 13 Lawrence X. Yu Bing V. Li Editors FDA Bioequivalence Standards AAPS Advances in the Pharmaceutical Sciences Series The AAPS Advances in the Pharmaceutical
More informationApplication of IVIVCs in Formulation Development Douglas F Smith
Application of IVIVCs in Formulation Development Douglas F Smith PQRI Workshop on Application of IVIVC in Formulation Development September 5-6, 2012 Bethesda, Maryland In Vitro/In Vivo Correlations -
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationBIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE. Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016
BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016 Introduction Early 1970 s FDA regulations for submission of BA data 1984 US Congress passed the
More informationAAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community)
AAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community) Faye Vazvaei, Roche Innovation Center New York The 8th JBF Meeting, 8-9 February 2017 Background
More informationCurrent Developments in Guidance for Regulatory Bioanalysis
Current Developments in Guidance for Regulatory Bioanalysis Dr Gerry McGuire Resolution Analytical Consultancy Ltd Edinburgh, Scotland UK gerry@resolutioneurope.com 1st MENA Regulatory Conference on Bioequivalence,
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationReview Article. FDA Critical Path Initiatives: Opportunities for Generic Drug Development
The AAPS Journal, Vol. 10, No. 1, March 2008 (# 2008) DOI: 10.1208/s12248-008-9010-2 Review Article Themed Issue: Bioequivalence, Biopharmaceutics Classification System, and Beyond Guest Editors: James
More informationBioavailability trial design for products delivered via the inhalation route
Bioavailability trial design for products delivered via the inhalation route Jianmeng Chen, Suresh Doddapaneni, Ping Ji, Chandrahas G Sahajwalla Division of Clinical Pharmacology 2 US FDA/CDER/OTS/OCP
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationDISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs
Issue: March 2016, Posted Date: 3/1/2016 DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs INTRODUCTION In the development of orally inhaled and nasal products
More informationAnnex I. Scientific conclusions and grounds for refusal presented by the European Medicines Agency
Annex I Scientific conclusions and grounds for refusal presented by the European Medicines Agency Scientific conclusions and grounds for refusal presented by the European Medicines Agency Overall summary
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationDraft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016
15 December 2016 Committee for Medicinal Products for Human Use (CHMP) Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More informationIntroduction to Bioequivalence
Wikimedia Commons 2006 Schwallex Creative Commons Attribution-ShareAlike 3.0 Unported Introduction to Bioequivalence Moscow, 23 May 2012 Добро пожаловать! Introduction to Bioequivalence Helmut Schütz BEBAC
More informationBiopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
More informationBiowaiver Study on Prednisolone Tablets 5 mg in Three Different Brands. Marketed in Sudan. Safaa Mohamed *, Tilal Elsaman
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9 [4]:8-114 [http://scholarsresearchlibrary.com/archive.html] ISSN 0975-5071 USA CODEN: DPLEB4
More informationLiposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation
Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry U.S. Department of Health and Human Services
More informationGuidance Document. Comparative Bioavailability Standards: Formulations Used for System Effects
Guidance Document Comparative Bioavailability Standards: Formulations Used for System Effects Date Adopted: 2012/12/08 Revised Date: 2018/06/08 Effective Date: 2018/07/01 (for submissions filed on or after
More informationAltered GI absorption in special populations: An industry perspective
Altered GI absorption in special populations: An industry perspective Cordula Stillhart and Neil J. Parrott F. Hoffmann La Roche Ltd, Basel (CH) UNGAP WG meeting, Leuven (B) 8 March 2018 Current challenges
More informationORANGE BOOK ORANGE BOOK
1 INTRODUCTION: DEFINITION: The official title of the book is Approved Drug Products with Therapeutic Equivalence Evaluations. Orange book is a publication by the Food and Drug Administration which contains
More informationEMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.
EMA/EGA Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr. Henrike Potthast Disclaimer The presentation reflects the personal opinion of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationMETHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE
METHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE INTRODUCTION: A multisource drug product is a drug product that contains the same active drug substance in the same dosage form and is marketed by
More information5.1 Summary. Summary & Conclusions
5.1 Summary The thesis can be summarized as follows: 1. Introduction- It is the first chapter of the thesis. It describes about the importance of generic products, its role in pharmaco-economics of India.
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationA Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data
A Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data IPAC-RS/UF Orlando Inhalation Conference March 18-20, 2014 Dennis Sandell, S5 Consulting Contents The data brief
More informationPublic Assessment Report Scientific discussion SE/H/1689/01/DC
Public Assessment Report Scientific discussion Budesonide/Formoterol Sandoz (budesonide, formoterol fumarate dehydrate) SE/H/1689/01/DC This module reflects the scientific discussion for the approval of
More information2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.
BIOPHARMACEUTICS Drug Product Performance Parameters: 1- Minimum effective concentration (MEC): The minimum concentration of drug needed at the receptors to produce the desired pharmacologic effect. 2-
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationSCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
More informationGeneric Drug Approval Process
1 Generic Drug Approval Process Sharon Ricciardo Katherine P. Weld. M.S., Ph.D. AAVPT Veterinary Drug Regulatory Life Cycle Course March 2, 2011 Overview Background Approval Process Bioequivalence Special
More informationAdapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016
Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence
More informationRole of Pharmacokinetics in Establishing Bioequivalence for Orally Inhaled Drug Products: Workshop Summary Report
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY Volume 24, Number 3, 2011 ª Mary Ann Liebert, Inc. Pp. 119 135 DOI: 10.1089/jamp.2011.0878 Meeting Report Role of Pharmacokinetics in Establishing
More informationA Review Article on Bioavailability and Bioequivalence Studies
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1711-1721, Oct-Dec 2013 A Review Article on Bioavailability and Bioequivalence Studies Srivastav Atul Kumar*,
More informationLessons Learned from Approval of Generic Nasal Products
Lessons Learned from Approval of Generic Nasal Products Julie D. Suman, Ph.D President, Next Breath IPAC-RS/UF Orlando Inhalation Conference: Approaches in International Regulation March 20, 2014 Objectives
More informationHelmut Schütz. Training on Bioequivalence Kaunas, 5 6 December
Dissolution / Biowaivers / IVIVC Helmut Schütz Training on Bioequivalence Kaunas, 5 6 December 2017 1 Human Guineapigs I BE as a surrogate for clinical efficacy / safety ( essential similarity ) We want
More informationConsiderations in establishing bioequivalence of inhaled compounds
Expert Opinion on Drug Delivery ISSN: 1742-5247 (Print) 1744-7593 (Online) Journal homepage: http://www.tandfonline.com/loi/iedd20 Considerations in establishing bioequivalence of inhaled compounds Irvin
More informationDevelopment of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid
Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid Joanne ( 乔安妮 ) Mather Senior Scientist Waters Corporation Data courtesy of Erin Chambers and Mary
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationReducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionkey/ms
Reducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionkey/ms Erin E. Chambers and Kenneth J. Fountain Waters Corporation, Milford,
More informationPK-UK Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability. Bath, November 2014
PK-UK 2014 Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability Bath, November 2014 Prof. Dr. Jennifer Dressman Dressman Bath 2014 Why IVIVC
More informationClinical Studies in BE Evaluation of Generic Products. Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs
Clinical Studies in BE Evaluation of Generic Products Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs 1 Disclaimer The opinions and information in this presentation
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationGuidance for Industry
Guidance for Industry Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation DRAFT GUIDANCE This guidance document is being
More informationPrasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance
31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April
More informationSpanish Interpretation and Application of the OIP Guideline DISCLAIMER
Spanish Interpretation and Application of the OIP Guideline Dr. Alfredo García - Arieta Head of the Service of Generics and Pharmacokinetics Division of Pharmacology and Clinical Evaluation Human Use Medicines
More information1 Introduction: The Why and How of Drug Bioavailability Research
j1 1 Introduction: The Why and How of Drug Bioavailability Research Han van de Waterbeemd and Bernard Testa Abbreviations ADME EMEA FDA NCE PD P-gp PK R&D Absorption, distribution, metabolism, and excretion
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationOptimising the application of in vitro test methods for the demonstration of bioequivalence in orally inhaled products
Optimising the application of in vitro test methods for the demonstration of bioequivalence in orally inhaled products Mark Copley, Director and Anna Sipitanou, Business Development Manager, Copley Scientific
More informationAbacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationPredictive modeling of deposition, dissolution, absorption and systemic exposure
Predictive modeling of deposition, dissolution, absorption and systemic exposure IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Per Bäckman and Bo Olsson, AstraZeneca R&D, Mölndal Sweden The views
More informationAdvantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems
Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems November 16 th Prof. Gregory E. Amidon - University of Michigan What is an In vivo Predictive Dissolution (IPD) System? An IPD
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More information